Both T cell priming in lymph node and CXCR3-dependent migration are the key events for predicting the response of atezolizumab.

Indeed, patients with no or low PD-L1 expression (TC0 and IC0) and a high blood-based tumor mutational burden score showed a trend towards a progression-free survival benefit 29 , and a patient with mismatch repair-deficient hepatoid adenocarcinoma of the lung was reported to respond to anti-PD-L1 therapy despite there being no PD-L1 expression in the tumor 30 .

also in 53,322 other papers